|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial显示文摘 | Mark A. Socinski Igor Bondarenko Nina A. Karaseva Anatoly M. Makhson Igor Vynnychenko Isamu Okamoto Jeremy K. Hon Vera Hirsh Paul Bhar Hui Zhang Jose L. Iglesias Markus F. Renschler | 2012 | Journal of Clinical Oncology2012，，17： | 3 |
| 2 | Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial显示文摘 | Robert Pirker Jose R Pereira Aleksandra Szczesna Joachim von Pawel Maciej Krzakowski Rodryg Ramlau Ihor Vynnychenko Keunchil Park Chih-Teng Yu Valentyn Ganul Jae-Kyung Roh Emilio Bajetta Kenneth O’Byrne Filippo de Marinis Wilfried Eberhardt Thomas Goddeme | 2009 | The Lancet2009，，9674： | 1 |
| 3 | First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination withfirst-line chemotherapy:a subgroup analysis of data fromthe FLEX phase 3 study显示文摘 | Gatzemeier U von Pawel J Vynnychenko I | 2011 | Lancet Oncol2011，12，1： | 1 |
| 4 | Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as ifrst-line therapy in patients with advanced non-small-cell lung cancer:ifnal results of a phase III trial显示文摘 | Socinski MA Bondarenko I Karaseva NA Makhson AM Vynnychenko I Okamoto I | | 0，，： | 1 |
| 5 | International, ran- domized, placebo-controlled, double-blind phase Ⅲ study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONETI显示文摘 | Scagliotfi GV Vynnychenko Ⅰ Park K | 2012 | J Clin Oncol2012，30，23： | 1 |
| 6 | International, ran- domized, placebo-controlled, double-blind phase Ⅲ study of motesanib plus carboplatirapaclltaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONETI显示文摘 | Scagliotfi GV Vynnychenko I Park K | 2012 | J Clin Oncol2012，30，23： | 1 |
| 7 | First-cycle rash and survival in patients with advanced non-small-cell lung cancer re- ceiving cetuximab in combination with first-line chemotherapy: a sub- group analysis of data from the FLEX phase 3 study显示文摘 | Gatzemeier U von-Pawel J Vynnychenko I | 2011 | Lancet On- col2011，12，1： | 1 |
| 8 | An international, randomized, placebo-controlled, double- blind phase Ⅲstudy (MONETI) of motesanib plus carboplatin/paclitaxel(C/P) in patients with advanced nonsquamous non-small cell lung cancer(NSCLC) 显示文摘 | Scagliotti G Vynnychenko I Ichinose Y | 2011 | J Clin Oncol2011，29，18： | 1 |
| 9 | International, randomized, placebo- controlled, doubl- blind phase Ⅲ study of motesanib plus carboplatin/paelitaxel in patients with advanced nonsquamous non- small- cell lung cancer: MONET 1显示文摘 | SCAGLIOTTI GV VYNNYCHENKO I PARK K | 2012 | J Clin Oneol2012，30，23： | 1 |
| 10 | First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy:a subgroup analysis of data from the FLEX phase3study显示文摘 | Gatzemeier U von Pawel J Vynnychenko I | 2011 | Lancet Oncol2011，12，1： | 1 |
| 11 | International, randomized, placebo-controlled, double-blind phaselll study ofmotesanib plus carboplatin/pactitaxel inpatients with advanced nonsquamous non-small-cell lung cancer: MONET1 显示文摘 | SCAGLIOTTI G V VYNNYCHENKO I PARK K | 2012 | -J Clin Oncol2012，30，23： | 1 |
| 12 | First-cy- cle rash and survival in patients with advanced non-small- cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study显示文摘 | Gatzemeier U von Pawel J Vynnychenko I | 2011 | Lancet Oncol2011，12，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员